Contingency Management for Opioid and Stimulant Use Disorders in Primary Care

Contingency Management as a Treatment for Opioid Use Disorder and Stimulant Use Disorder in a Primary Care Setting

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05288751

Enrollment

Registered

2022-03-21

Start date

2022-06-15

Completion date

2026-10-31

Last updated

2026-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid Use Disorder, Stimulant Use Disorder

Keywords

opioid use disorder, stimulant use disorder, contingency management, primary care, addiction medicine, buprenorphine

Brief summary

Contingency management (CM) is a behavioral intervention that involves incentivizing participants for target behaviors in a clinical setting. When applied to the treatment of substance use disorders, it has demonstrated efficacy in reducing the number of urine toxicology screens positive for illicit substances and increased engagement in treatment programs. However, there is a need to translate CM treatment to primary care settings. This study will implement and assess a CM program for patients with opioid use disorder, with or without comorbid stimulant use disorder, initiating outpatient addiction medicine services at a family medicine residency clinic. Eligible patients will earn monetary incentives for attending addiction medicine appointments and abstaining from substances during outpatient treatment. Data gathered from this pilot program will be used to improve patient outcomes, treatment, and retention for persons receiving medications for opioid use disorder (MOUDs) in a primary care setting.

Interventions

BEHAVIORALContingency Management

Contingency management (CM) is a behavioral intervention that involves incentivizing participants for target behaviors in a clinical setting.

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* At least 18 years of age * Diagnosis of Opioid Use Disorder and/or Stimulant Use Disorder * Recently initiated medications for opioid use disorder (MOUDs) at Broadway Family Medicine (BFM), within 2 weeks of recruitment * Have an active prescription for buprenorphine-naloxone (Suboxone)

Exclusion criteria

* Prescription for an amphetamine would exclude patients from the abstinence-based CM, but they could participate in the attendance-only CM. * Dementia, development disabilities, or cognitive functioning that is too low to participate in study measures, as determined by chart review and consultation with overseeing physician.

Design outcomes

Primary

Measure	Time frame	Description
Preliminary efficacy of CM on clinical outcomes: Visit Frequency	30 days post-intervention	Number of completed clinical visits per patient during the CM program.
Preliminary efficacy of CM on clinical outcomes: Urine toxicology	30 days post-intervention	Percentage of UDS results that are negative for stimulants during the CM intervention period.
Feasibility of CM for OUD in primary care: Recruitment	30 days post-intervention	percentage of patients invited to participate enroll in the treatment intervention.
Feasibility of CM for OUD in primary care: Retention	30 days post-intervention	Of those patients who enroll in the intervention study, the percent that complete the CM intervention period.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORRobert Levy, MD

University of Minnesota

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 17, 2026